A new study out of Finland, published by the U.S. National Institute of Health and the journal Duodecim, has found that cannabis significantly improved the quality of life for a patient with cerebral palsy.
“Cannabinoid was licensed in 2012 for the treatment of spasticity associated with multiple sclerosis in Finland”, states the study. “Spasticity is one of the main symptoms in cerebral palsies and a risk factor of multiple painful anomalies of the skeletal network. We describe a 28-year-old man with severe cerebral palsy, whose quality of life improved and the need for help decreased by using two daily mouth sprays of cannabinoid.”
Although the study used just one patient, the conclusive results will hopefully lead to further research on the subject, in order to help validate the study’s claims.
According to the National Library of Medicine, celebral palsy is “a group of disorders that can involve brain and nervous system functions, such as movement, learning, hearing, seeing, and thinking. There are several different types of cerebral palsy, including spastic, dyskinetic, ataxic, hypotonic, and mixed.”